EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates

Alef D S Lima, Lídia M Lima iD

Pharmaceuticals · 12.01.2026 · 19 (1) · 130

DOI: 10.3390/ph19010130 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 12.01.2026. Verfasst von Alef D S Lima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for the Evaluation and Synthesis of Bioactive Substances (LASSBio®), National Institute of Science and Technology for Drugs and Medicines …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Science and Technology of Drugs and Medicines, National Council for Scientific and Technological Development, FAPERJ.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phosphatidylinositol-3-kinases (PI3Ks) constitute an important validated therapeutic class involved in crucial cellular processes, and their dysregulation is associated with cancer initiation and progression. Nonetheless, intrinsic and acquired resistance mechanisms associated with PI3K pathway modulation have underscored the need for alternative therapeutic strategies. In this context, recent studies have shown that simultaneous inhibition of PI3K and histone deacetylases (HDAC) promotes synergistic antitumor effects in different cancer cell lines. HDACs are validated epigenetic targets that are extensively explored in clinical practice and have a pharmacophore with versatility for structural modifications, which facilitates the design of multitarget inhibitors. This review examines the rational design and synthetic evolution of dual PI3K/HDAC inhibitors, an area catalyzed by the development of fimepinostat, the first clinically evaluated agent exhibiting potent and balanced inhibition of both targets. We provide a critical overview of PI3K/HDAC multitarget inhibitors reported in recent years that have progressed to preclinical or clinical investigation, discussing the structural frameworks employed, medicinal chemistry strategies adopted, and structure–activity relationships established. Particular attention is given to advantageous molecular features as well as challenges related to toxicity, pharmacokinetic behavior, and pharmacodynamic modulation. From this comprehensive analysis, we outline key considerations and emerging design principles that may inform the next generation of PI3K/HDAC multitarget drug candidates. Insights derived from the diversity of chemical scaffolds, activity profiles, and selectivity patterns described herein may support the development of innovative therapeutic agents capable of overcoming current limitations in anticancer treatment.

Schlagwörter

Stichwörter der Autor:innen

HDAC and PI3K inhibitioncancermultitarget-directed ligands

Autor:innen und Institutionen

  • Laboratory for the Evaluation and Synthesis of Bioactive Substances (LASSBio®), National Institute of Science and Technology for Drugs and Medicines (INCT-INOFAR), Federal University of Rio de Janeiro, Rio de Janeiro 21…
  • Graduate Program in Chemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, RJ, Brazil.

ORCID-Profile: Lídia M Lima

Förderung

  • National Institute of Science and Technology of Drugs and Medicines
  • National Council for Scientific and Technological Development
  • FAPERJ
  • Coordenação de Aperfeicoamento de Pessoal de Nível Superior
  • INCT-INOFAR
  • CNPq
  • CAPES

Zitieren

APA

Lima, A. D. S., & Lima, L. M. (2026). Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. Pharmaceuticals, 19(1), 130. https://doi.org/10.3390/ph19010130

Vancouver

Lima ADS, Lima LM. Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. Pharmaceuticals. 2026;19(1):130. doi:10.3390/ph19010130

BibTeX
@article{Lima2026,
  author = {Lima, Alef D S and Lima, Lídia M},
  title = {Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {130},
  doi = {10.3390/ph19010130}
}
Kostenlos starten →